All In Biotech

Drug Trial Radar · NCT04085523

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension Period

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

57

Actual

Start

Jun 24, 2020

Primary completion

Sep 27, 2022

Study completion Oct 1, 2024

Sponsor

Lead sponsor
Ascendis Pharma A/SIndustry
Sponsor type
Industry
First posted
Sep 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial is a multicenter, double-blind, randomized, placebo-controlled, dose escalation trial of weekly TransCon CNP administered subcutaneously in prepubertal children 2 to 10 years old, inclusive, with Achondroplasia.

Conditions

  • Achondroplasia

Interventions

  • TransCon CNPDrug

    TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

  • Placebo for TransCon CNPDrug

    Weekly subcutaneously injection of placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Height Velocity (cm/Year) After 52 Weeks of Double-blind TreatmentTime frame: 52 weeks

Locations

15 sites in 8 countries. Site status is shown where the registry gives one.

  • Ascendis Pharma Investigational Site

    Little Rock, Arkansas

  • Ascendis Pharma Investigational Site

    Aurora, Colorado

  • Ascendis Pharma Investigational Site

    Saint Paul, Minnesota

  • Ascendis Pharma Investigational Site

    Columbia, Missouri

  • Ascendis Pharma Investigational Site

    Buffalo, New York

  • Ascendis Pharma Investigational Site

    Houston, Texas

  • Ascendis Pharma Investigational Site

    Seattle, Washington

  • Ascendis Pharma Investigational Site

    Madison, Wisconsin

  • Ascendis Pharma Investigational Site

    Parkville, Victoria, Australia

  • Ascendis Pharma Investigational Site

    Linz, Austria

  • Ascendis Pharma Investigational Site

    Copenhagen, Denmark

  • Ascendis Pharma Investigational Site

    Berlin, Germany

  • Ascendis Pharma Investigational Site

    Dublin, Ireland

  • Ascendis Pharma Investigational Site

    Auckland, New Zealand

  • Ascendis Pharma Investigational Site

    Coimbra, Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.